NFE2L2 and atherosclerosis: A growing number of clinical trials on sirtuin- and NAD+-boosting therapies report beneficial effects on arterial stiffening, atherosclerosis and coronary artery disease49,50, underscoring the translational potential of Sirt1/Nrf2-targeting interventions.